DiaMedica Therapeutics (NASDAQ:DMAC) Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for acute and chronic conditions in neurology, ophthalmology and cardio-renal medicine. The company’s lead candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to address unmet medical needs in acute ischemic stroke, neurodegenerative diseases and renal impairment. DiaMedica’s research efforts focus on leveraging the unique properties of tissue kallikrein pathways to promote tissue repair, reduce inflammation and improve functional outcomes following injury.
DiaMedica’s pipeline is anchored by DM199, which is currently being evaluated in multiple Phase II clinical trials. A key program investigates the potential of DM199 to reduce the extent of brain injury and improve neurological recovery in patients suffering from ischemic stroke. In parallel, the company is exploring the application of its kallikrein platform in chronic kidney disease and eye disorders, aiming to expand the therapeutic scope of its lead molecule. DiaMedica complements its core development activities with preclinical research on novel indications and formulations to maximize patient benefit.
Founded in 2013 and headquartered in Minneapolis, Minnesota, DiaMedica has established operations in both the United States and Europe, enabling collaborations with leading academic centers and contract research organizations. The company pursues strategic partnerships and licensing agreements to access complementary technologies and accelerate clinical development. DiaMedica’s management team combines industry veterans with scientific experts in drug discovery, clinical development and regulatory affairs to advance its programs efficiently through global regulatory pathways.
Under the leadership of President and CEO Donna R. Cambareri, DiaMedica has built a lean organizational structure designed to adapt quickly to evolving scientific and clinical landscapes. The company’s strategy emphasizes rigorous clinical evaluation, risk-adjusted investment in pipeline programs and transparent engagement with regulators, investors and patient advocacy groups. As DiaMedica advances its clinical candidates toward pivotal studies, it remains focused on delivering transformative therapies for serious medical conditions with high unmet need.
